斯鲁利单抗联合白蛋白紫杉醇+顺铂在晚期肺鳞状细胞癌患者中的应用效果  

Application effect of serplulimab combined with albumin paclitaxel+cisplatin in patients with advanced lung squamous cell carcinoma

作　　者：张少迪 肖永生 吴茱萸[1] ZHANG Shaodi;XIAO Yongsheng;WU Zhuyu(Department of Respiratory and Critical Care Medicine,Luohe Central Hospital,Luohe 462000,He’nan,China;Department of General Practice Medicine,Luohe Central Hospital,Luohe 462000,He’nan,China)

机构地区：[1]漯河市中心医院呼吸与危重症医学科,河南漯河4620000 [2]漯河市中心医院全科医学科

出　　处：《癌症进展》2024年第20期2282-2285,共4页Oncology Progress

摘　　要：目的探讨斯鲁利单抗联合白蛋白紫杉醇+顺铂在晚期肺鳞状细胞癌患者中的应用效果。方法依据治疗方法的不同将107例晚期肺鳞状细胞癌患者分为对照组(n=52)和观察组(n=55),对照组患者接受白蛋白紫杉醇+顺铂治疗,观察组患者接受斯鲁利单抗联合白蛋白紫杉醇+顺铂治疗。比较两组患者的临床疗效、生活质量[生活质量综合评定问卷-74(GQOLI-74)]及不良反应发生情况;采用Kaplan-Meier法绘制生存曲线,组间比较采用Log-rank检验。结果观察组患者的治疗总有效率为63.64%,高于对照组患者的44.23%,差异有统计学意义(P﹤0.05)。治疗后,两组患者GQOLI-74各维度评分均高于本组治疗前,观察组患者GQOLI-74各维度评分均高于对照组,差异均有统计学意义(P﹤0.05)。观察组患者的不良反应总发生率为23.64%,与对照组患者的28.85%比较,差异无统计学意义(P﹥0.05)。随访1年,观察组患者的总生存率为49.1%,明显高于对照组患者的28.8%,差异有统计学意义(P﹤0.01)。结论斯鲁利单抗联合白蛋白紫杉醇+顺铂能提高晚期肺鳞状细胞癌患者的临床疗效和生活质量,提高生存率,且安全性较高。Objective To explore the application effect of serplulimab combined with albumin paclitaxel+cisplatin in patients with advanced lung squamous cell carcinoma.Method According to different treatment methods,107 patients with advanced lung squamous cell carcinoma were divided into control group(n=52)and observation group(n=55).Patients in the control group received albumin paclitaxel+cisplatin treatment,while patients in the observation group received serplulimab combined with albumin paclitaxel+cisplatin treatment.The clinical efficacy,quality of life[generic quality of life inventory-74(GQOLI-74)],and incidence of adverse reactions were compared between the two groups.The survival curve was plotted by Kaplan-Meier method,and Log-rank test was used for comparisons between the two groups.Result The total effective rate in observation group was 63.64%,which was higher than 44.23%in control group,and the difference was statistically significant(P<0.05).After treatment,the scores of dimensions of GQOLI-74 in both groups were higher than those before treatment,the scores of dimensions of GQOLI-74 in observation group were higher than those in control group,and the differences were statistically significant(P<0.05).The total incidence of adverse reactions in observation group was 23.64%,which was not statistically significant compared to 28.85%in control group(P>0.05).After one-year follow-up,the overall survival rate in observation group was 49.1%,which was significantly higher than 28.8%in control group,and the difference was statistically significant(P<0.01).Conclusion Serplulimab combined with albumin paclitaxel+cisplatin can improve the clinical efficacy and quality of life of patients with advanced lung squamous cell carcinoma,increase survival rate,and have high safety.

关 键 词：斯鲁利单抗 白蛋白紫杉醇 顺铂 晚期肺鳞状细胞癌 

分 类 号：R734.2[医药卫生—肿瘤]